Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: CHF5993, CHF5259, Moxifloxacin 400mg, CHF5993 Placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hereditary Angioedema, HAE
Interventions: BCX7353 capsules, Placebo oral capsule; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 27
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more

Conditions: NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Interventions: Satralizumab, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 11
States / cities: Birmingham, Alabama • Newport Beach, California • San Francisco, California + 7 more

Conditions: Diabetic Macular Edema
Interventions: KVD001 Injection, Sham Procedure; Drug · Other
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 28 more

Conditions: Acute Decompensated Heart Failure, Congestive Heart Failure
Interventions: Aliskiren, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 37
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more

Conditions: Alzheimer Disease
Interventions: Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Scottsdale, Arizona • Anaheim, California • Fresno, California + 34 more

Conditions: Skin and Subcutaneous Tissue Bacterial Infections, Gram-Positive Bacterial Infections
Interventions: TNP-2092, Vancomycin; Drug
Lead sponsor: TenNor Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Mitochondrial Myopathy
Interventions: elamipretide (low dose), elamipretide (intermediate dose), elamipretide (high dose), Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more

Conditions: Primary Biliary Cholangitis
Interventions: Saroglitazar magnesium 1 mg, Placebo; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: Marietta, Georgia • Indianapolis, Indiana • Houston, Texas

Conditions: Primary Sclerosing Cholangitis
Interventions: Anti-human CCL24 monoclonal antibody (CM-101), Placebo; Biological · Other
Lead sponsor: ChemomAb Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 8
States / cities: La Jolla, California • Sacramento, California • Chicago, Illinois + 4 more

Conditions: Schizophrenia or Schizoaffective Disorder
Interventions: AMG 581, Placebo, Midazolam; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Glendale, California

Conditions: Asthma
Interventions: Placebo, Benralizumab 25 mg, Benralizumab 100 mg, Benralizumab 200 mg; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Encinitas, California • Los Angeles, California • Colorado Springs, Colorado + 3 more

Conditions: Depressive Disorder, Major
Interventions: Sirukumab 50 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 21 Years to 64 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 21 more

Conditions: Asthma
Interventions: AMG 827, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 22
States / cities: Encinitas, California • Huntington Beach, California • Los Angeles, California + 19 more

Conditions: Burns
Interventions: Caldolor, Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Orlando, Florida • Winston-Salem, North Carolina

Conditions: Hypotrichosis
Interventions: Track A, Track B; Drug
Lead sponsor: ATS Clinical Research; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Primary Open Angle Glaucoma, Open Angle Glaucoma
Interventions: Minimally Invasive Micro Sclerostomy Device; Device
Lead sponsor: Sanoculis Ltd; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Schizophrenia
Interventions: PF-02545920, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 44
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 35 more

Conditions: HIV-1
Interventions: 3BNC117-LS, 10-1074-LS, Sterile Saline; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Bethesda, Maryland • New York, New York

Conditions: Radiation Safety
Interventions: Radiation Alert, Control; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: Not listed
Enrollment: 15,969 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Prostate Cancer
Interventions: Atrasentan; Drug
Lead sponsor: Abbott; Industry
Eligibility: 19 Years and older · Male only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 79
States / cities: Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 66 more

Conditions: Healthy Volunteers
Interventions: E2730, E2730-matched placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Generalized Myasthenia Gravis
Interventions: M281, Placebo; Drug · Other
Lead sponsor: Momenta Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 31
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more

Conditions: Cystic Fibrosis
Interventions: tiotropium Respimat® inhaler, Placebo Respimat® inhaler; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: Not listed
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 15
States / cities: Tuscon, Arizona • San Diego, California • Jacksonville, Florida + 10 more

Search by objective public record fields.

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy

Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes

CM-101 in PSC Patients -The SPRING Study

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma

Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients

Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

Radiation Safety Alert

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

Tiotropium Bromide in Cystic Fibrosis